Creative Biolabs offers clients DVD-IgG, a novel format of bispecific antibodies (BsAbs), design and construction services for many diverse studies in both academic and clinical purposes. We serve our customers with timely quotation, the most competitive price, high quality services and fast delivery cycle.
In the recent years, production of BsAbs which have the ability to recognize two different antigens simultaneously has become a trend of engineering antibodies. A variety of recombinant techniques have been developed to synthesize BsAbs. Furthermore, two-in-one antibodies, which formed a surface that specifically binds two target antigens with high affinity through a single antibody binding site, have aroused much interest in the field. In addition, the in vivo features, including stability, pharmacokinetics, and effector function, of the IgG-based BsAbs are expected to be similar to those of classical monoclonal antibodies, which are essential for clinical use.
Based on the design of two-in-one antibodies, Creative Biolabs offers IgG-based tetra-specific antibodies by current antibody engineering methodologies, named as DVD-IgG. DVD-IgG is a kind of IgG-based heterodimeric and tetra-specific antibody format, which is generated by using cutting-edge antibody engineering strategies. It is constructed by fusing two DVD-IgG antibodis with distinct specificity via the “knobs into holes” (KIH) and the CrossMab methods. Besides the antigen-binding specificity, affinity, and biologic activities of its parental antibodies, the DVD-IgG has two new additional domains. Therefore, it is a four-in-one IgG form, which is able to simultaneously recognize 4 target antigens without changing the high affinity of its parental antibodies. The design and manufacture of DVD-IgGs have aroused abundant interests in the bispecific antibody engineering field for disease treatments.
Figure 1. Schematic representation of the DVD-IgG antibody. (Spiess, C., 2015)
Researchers have successfully developed two DVD-IgGs: FL518 and CRTB6. FL518 is produced from two-in-one antibodies, bH1-44 and MEHD7945A, while CRTB6 is able to simultaneously bind to one EGFR, one HER2, one HER3, and one VEGF. Contrast to two-in-one antibodies and many BsAbs in multiple tumor models, FL518 and CRTB6 were more extensively efficacious. They also demonstrated that tetra-specific antibodies were far more effective than BsAbs in inhibiting the growth of anti–HER-resistant cancer cells, which displayed improved levels of MET activation both in vitro and in vivo.
Figure 2. Schematic representation of the four-in-one antibody FL518 (Hu, S., 2015).
With the well-established DVD-IgG technology platform, the experienced scientists here at Creative Biolabs are dedicated to help you develop therapeutic BsAbs. We also provide other various services regarding BsAbs development. Please feel free to contact us for more information and a detailed quote.
1. Hu, S.; et al. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer research. 2015, 75(1): 159-170.
2. Spiess, C.; et al. Alternative molecular formats and therapeutic applications for bispecific antibodies. Molecular immunology. 2015, 67(2): 95-106.